[Adverse cutaneous reactions to erlotinib]
G Pitarch1, J Garde, A Torrijos
1Servicio de Dermatología. Consorci Hospital General Universitari de València. Valencia. España. gerardpitarch@hotmail.com
Actas Dermo-Sifiliograficas
|January 22, 2008
Summary
Erlotinib treatment frequently causes skin issues like acneiform eruption and paronychia. Management often involves topical treatments or temporary drug suspension.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Erlotinib is a targeted therapy for non-small cell lung cancer.
- Adverse cutaneous reactions are known side effects of erlotinib.
- Understanding the prevalence and management of these reactions is crucial.
Purpose of the Study:
- To determine the prevalence of skin reactions in patients receiving erlotinib.
- To assess the management strategies for these adverse cutaneous events.
- To document the time course of various dermatological side effects.
Main Methods:
- Prospective observational study design.
- Involved 12 patients (11 lung cancer, 1 ovarian cancer) on erlotinib 150 mg/d.
- Assessed prevalence, severity, and onset of cutaneous reactions.
Main Results:
- Acneiform eruption was the most common reaction (10/12 patients).
- Other frequent reactions included seborrheic dermatitis (5/12) and paronychia (4/12).
- Onset varied, with dermatitis and acne appearing early, and paronychia later; some patients required treatment suspension.
Conclusions:
- Erlotinib treatment is associated with a high incidence of adverse cutaneous effects.
- Acneiform eruption, seborrheic dermatitis, and paronychia are the most prevalent skin reactions.
- These reactions may necessitate temporary cessation of erlotinib therapy.
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...